Score Your Stock

US stock · figures in US dollars · scored on full-year results

Zoetis Zoetis Inc. Class A Common Stock

ZTS · Healthcare · Drug Manufacturers - Specialty & Generic
Top 42% of scored stocks
OkayTop 42% of scored stocks
Weak Spot

Zoetis scores 57/100 on fundamentals: in the top 42% of 503 scored S&P 500 stocks. Its strongest area is Business Strength (70/100); its weakest is Price Fairness (17/100). It carries 1 warning flag: Weak Spot.

Best
Business 70
Weakest
Price 17
  • Carries a Weak Spot flag

This stock is fairly balanced overall: price fairness is its weakest area.

What looks good
What to watch
Mkt capUS$ 32.9b#309 of 503 in the S&P 500EPSUS$ 6.08P/E12.5×✓ vs sector median 30.5×P/B10.5×✗ vs sector median 3.7×Div yield3%✓ Top 24% in the S&P 50052w range · 14% of range68.77144.83
as of 31 Oct 2026

Nearby peers

Ranks #24 of 60 in Healthcare by score

#1Universal Health Services79#22Agilent Technologies57#23Edwards Lifesciences57
#24Zoetis57
#25DaVita56#26Bristol Myers Squibb55

One-Minute Summary

Why Zoetis scores 57

This stock is fairly balanced overall: price fairness is its weakest area.

What looks good
What to watch

Business Strength

70
Why 70?
Pillar score: (2 + 1 + 1 + 2 + 1) = 7 of 10 points → 70
Return on Equity (ROE)84%Strong4-Year Revenue Growth+4%/yrOkay4-Year Profit Growth+4%/yrOkayNet Profit Margin28%StrongQuarterly Momentum+1%Okay
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↑ +12.5%Equity ↓ -37%ROE % 83.8%
Net ProfitEquityROE %
2.3b2.5b2.7b2.6b5.0b4.8b3.3b3.1b202320242025TTM46.9%52.1%80.2%83.8%

Revenue & Net Profit, with Net Margin

Revenue ↑ +11.5%Net Profit ↑ +12.5%Net Margin % 27.7%
RevenueNet ProfitNet Margin %
8.5b9.3b9.5b9.5b2.3b2.5b2.7b2.6b202320242025TTM27.4%26.9%28.2%27.7%

Sales grew about 11.5% over 4 years: customers keep spending more with this company.

Profit climbed about 12.5% over 4 years: the business keeps more money as it grows.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +3.4%Net Profit → +1.3%Net Margin % 28%
RevenueNet ProfitNet Margin %
2.4b2.3b2.2b2.5b2.4b2.4b2.3b2.5b682m581m602m726m721m603m601m691mQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'2628.6%25.1%27.4%29.3%30%25.3%26.6%28%
▲▲▬▲▲▬▬▬

Sales have stayed roughly flat over the last 8 quarters.

Profit has moved sideways over the last 8 quarters.

Why 67?
Pillar score: (0 + 2 + 2) = 4 of 6 points → 67
Debt-to-Equity2.9×WeakCurrent Ratio3.1×StrongInterest Coverage14.9×Strong
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↑ +36.8%Equity ↓ -37%D/E 2.9×
Total DebtEquityD/E
6.8b6.7b9.2b9.2b5.0b4.8b3.3b3.1b202320242025TTM1.4×1.4×2.8×2.9×

Borrowings grew about 36.8% over 4 years: watch this; rising debt adds pressure in bad times.

Short-term assets vs bills, with Current Ratio

Current Assets → +0.2%Current Liabilities ↑ +9.1%Current Ratio 3.1×
Current AssetsCurrent LiabilitiesCurrent Ratio
6.3b6.0b6.8b6.4b1.9b3.4b2.2b2.1b202320242025TTM3.4×1.8×3×3.1×
Why 63?
Pillar score: (0 + 2 + 2 + 1) = 5 of 8 points → 63
Dividend Quality3%Weak
Payout ratio: 34%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsPartly healthyOkay
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +20.7%Free CF ↑ +42.9%
Operating CFFree CF
2.4b3.0b2.9b2.8b1.6b2.3b2.3b2.3b202320242025TTM

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash ↓ -27.8%Total Debt ↑ +36.8%
CashTotal Debt
2.0b2.0b2.3b1.5b6.8b6.7b9.2b9.2b202320242025TTM

Dividends per Share, with Yield

DPS (cents) ↑ +53.8%Yield % 2.7%
DPS (cents)Yield %
32.532.537.537.543.243.2505050130150172.820020222023202420250.8%0.9%1%2.7%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 17?
Pillar score: (1 + 0 + 0) = 1 of 6 points → 17
P/E Ratio12.5×OkayP/B Ratio10.5×WeakPEG Ratio3.1Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 141.87US$ 105.78US$ 69.69Oct '25Feb '26Jun '26Oct '26

The share price is down about 43.8% over the past year.

Why 67?
Pillar score: (2 + 0 + 2 + 2 + 1 + 1) = 8 of 12 points → 67
Earnings ConsistencySteadyStrongDebt Trend (4yr)RisingWeakShare Count Trend (4yr)-3%/yrStrongInventory vs Sales (4yr)-3.6 pp/yr vs salesStrongAsset Turnover Trend (4yr)+5.6%OkayQuarterly Consistency2 of 4 quarters downOkay
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +11.5%Inventory → +0.4%Inv. % of Rev. 27%
RevenueInventoryInv. % of Rev.
8.5b9.3b9.5b9.5b2.6b2.3b2.4b2.6b202320242025TTM30%24.9%25.7%27%
Ranks #24 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#22Agilent Technologies57#23Edwards Lifesciences57
#24Zoetis (you)57
#25DaVita56#26Bristol Myers Squibb55

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDividend Payout RatioDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 9.5bUS$ 2.6bUS$ 2.8bUS$ 2.3bUS$ -524.0mUS$ 1.5bUS$ 9.2b-US$ 3.1bUS$ 6.4bUS$ 2.1bUS$ 15.1bUS$ 11.9bUS$ 2.6b-84%28%2.9×3.1×14.9×34%----
2025US$ 9.5bUS$ 2.7bUS$ 2.9bUS$ 2.3bUS$ -621.0mUS$ 2.3bUS$ 9.2b-US$ 3.3bUS$ 6.8bUS$ 2.2bUS$ 15.5bUS$ 12.1bUS$ 2.4bUS$ 200.0m80%28%2.8×3.0×16.1×33%2%19.7×15.8×2.4
2024US$ 9.3bUS$ 2.5bUS$ 3.0bUS$ 2.3bUS$ -655.0mUS$ 2.0bUS$ 6.7bUS$ 1.4bUS$ 4.8bUS$ 6.0bUS$ 3.4bUS$ 14.2bUS$ 9.5bUS$ 2.3bUS$ 172.8m52%27%1.4×1.8×14.9×32%1%28.6×14.9×4.2
2023US$ 8.5bUS$ 2.3bUS$ 2.4bUS$ 1.6bUS$ -732.0mUS$ 2.0bUS$ 6.8bUS$ 3.0mUS$ 5.0bUS$ 6.3bUS$ 1.9bUS$ 14.3bUS$ 9.3bUS$ 2.6bUS$ 150.0m47%27%1.4×3.4×13.3×30%1%37.1×17.4×2.9